Skip to Main Content

Pear Therapeutics has struck a deal to license voice biomarkers to try to improve treatment for patients with illnesses ranging from Alzheimer’s to insomnia and substance use disorder.

In a flurry of announcements Tuesday, the Boston-based company said it is licensing voice biomarker technology from Winterlight Labs Inc., a startup from Toronto that uses machine learning to pinpoint vocal changes associated with the onset of dementia and psychiatric diseases.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!